Trial results

$MIRM — volixibat

Mirum Pharmaceuticals, Inc. (MIRM) volixibat: trial results in primary biliary cholangitis (PBC), 2027.

Research by Catalyst Intel

The catalyst

"We expect topline data from our PBC study of volixibat in the first quarter of 2027."

— Mirum Pharmaceuticals, Inc., 10-Q filed 2026-11-03 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

MIRM-VOLIXIBAT-2026

Company

Mirum Pharmaceuticals, Inc.

Kind

Trial results

Indication

primary biliary cholangitis (PBC)

Window

2027-01-01 – 2027-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.